Table 4.
Method | ROW | ARI_a | ARI_p | ARI_o | ARI_c | EAR_Fd |
---|---|---|---|---|---|---|
(A) 25 trials | ||||||
Proposed | 0 | 0.239 | 0.932 | 0.201 | 0.720 | 0.866 |
w/o MEC-II | 0 | 0.299 | 0.971 | 0.207 | 0.717 | 0.723 |
mMLDA | 0 | 0.255 | 0.959 | 0.226 | 0.703 | – |
Proposed | 30 | 0.297 | 0.879 | 0.227 | 0.702 | 0.751 |
w/o MEC-II | 30 | 0.242 | 0.980 | 0.218 | 0.683 | 0.601 |
mMLDA | 30 | 0.296 | 0.893 | 0.256 | 0.730 | – |
Proposed | 50 | 0.240 | 0.905 | 0.257 | 0.681 | 0.604 |
w/o MEC-II | 50 | 0.224 | 0.895 | 0.211 | 0.694 | 0.482 |
mMLDA | 50 | 0.221 | 0.981 | 0.303 | 0.688 | – |
(B) 40 trials | ||||||
Proposed | 0 | 0.304 | 0.960 | 0.240 | 0.691 | 0.988 |
w/o MEC-II | 0 | 0.282 | 0.986 | 0.190 | 0.729 | 0.763 |
mMLDA | 0 | 0.290 | 0.959 | 0.224 | 0.736 | – |
Proposed | 30 | 0.303 | 0.978 | 0.193 | 0.698 | 0.829 |
w/o MEC-II | 30 | 0.349 | 0.917 | 0.219 | 0.726 | 0.718 |
mMLDA | 30 | 0.307 | 0.956 | 0.159 | 0.717 | – |
Proposed | 50 | 0.316 | 0.922 | 0.199 | 0.718 | 0.668 |
w/o MEC-II | 50 | 0.258 | 0.937 | 0.210 | 0.726 | 0.639 |
mMLDA | 50 | 0.297 | 0.989 | 0.123 | 0.687 | – |
Bold and underscore indicate the highest evaluation values, and bold indicates the second highest evaluation values.